Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.

The results further undermine Relvar Ellipta, which is already struggling ... FF/VI was administered once daily via the Ellipta inhaler. Patients who were taking a LAMA in addition to ICS/LABA ...

The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ...

BURLINGAME, Calif., December 16, 2024--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced ...

Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement ...

BURLINGAME, Calif., December 16, 2024--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive ...